PMID: 1861221Aug 1, 1991Paper

Dose-dependent kinetics of orally administered 6-mercaptopurine in children with leukemia

The Journal of Pediatrics
Y KatoT Ishizaki


To determine whether the pharmacokinetics of 6-mercaptopurine (6-MP) would show dose dependency, we studied three different single oral doses in eight children (aged 3.6 to 15.1 years) with acute leukemia in remission. Marked interindividual differences in maximum plasma concentration (Cmax) and the area under the plasma concentration-time curve (AUC) were observed when children received the 50 mg/m2 dose. This variability decreased when the doses were increased. Six of the eight children showed a disproportionate increase in the AUC with increasing doses; the other two had a proportionate relationship between the AUC and dose. Overall mean (+/- SD) Cmax and AUC values increased disproportionately (88 +/- 123, to 326 +/- 194, to 653 +/- 344 ng/ml for Cmax, and 147 +/- 180, to 451 +/- 177, to 1291 +/- 415 ng/ml per hour for AUC, respectively) when the dose increased from 50 to 87.5 mg/m2 and then to 175 mg/m2. The results suggest that a saturable first-pass metabolism of oral 6-MP occurs with increasing oral doses in some, but not all, children. Whether and to what extent this pharmacokinetic character of oral 6-MP affects the interindividual difference in systemic exposure to the drug in children with leukemia receiving mainten...Continue Reading


Jul 5, 1990·The New England Journal of Medicine·G KorenM Greenberg
Jan 1, 1989·Pharmacology & Therapeutics·R Weinshilboum
Apr 1, 1986·British Journal of Clinical Pharmacology·D M GrantW Kalow
Jan 1, 1985·Medical and Pediatric Oncology·R SeshadriJ M Skinner
Jan 1, 1985·Drug Metabolism Reviews·K G Van ScoikW R Porter
Apr 1, 1973·Biochemical Genetics·H Brunschede, R S Krooth
Jul 1, 1983·Clinical Pharmacokinetics·T H GraselaK Chiba
Jul 1, 1983·Journal of Pharmaceutical Sciences·B M SilberS Riegelman

❮ Previous
Next ❯


Oct 12, 1999·Journal of Chromatography. B, Biomedical Sciences and Applications·Y SuM V Relling
Apr 11, 2012·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Harpreet K DhaliwalLynne Lennard
Apr 15, 2011·Cancer Treatment Reviews·Hendrik van den BergJos H Beijnen
Dec 8, 2004·Critical Reviews in Oncology/hematology·E GroningerS S N de Graaf
May 5, 2020·Alimentary Pharmacology & Therapeutics·Albert J Czaja

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.